U.S. FDA Approves First PD-L1 Blocker for cSCC
The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Cosibelimab-ipdl is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA […]